We are pleased to be showcasing the progress of the Biosceptre Adaptor CAR-T platform this week at the ANZ BIOLOGICS FESTIVAL 2026 in Melbourne.
CEO Gavin Currie will be sharing the latest results that demonstrate the enhanced power of the Biosceptre BridgeCAR™ platform. The system combines the potency of CAR-T cell therapy with the flexibility and control of antibodies to deliver a complete platform approach ready for the next era of oncology investment.
Mr Gavin Currie: “Our Proprietary Modular CAR-T Platform Delivers Flexibility, Specificity, And Potency for CD33-targeted AML Treatment”
- Innovative modular CAR-T platform built on a proprietary, in-house–developed mechanism of action.
- Flexible, highly specific, and potent, enabling precise targeting with strong anti-tumor activity
- Clinic-ready CD33-targeted AML module, positioned for first-in-human evaluation
Date: Wednesday Feb 4th @11:25am (AEDT)